NCT07413354招募中2 期
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Prospective Clinical Trial
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 94
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule. By comparing the objective response rate (ORR) and other data with those from the historical Rational 301 study, the study aims to explore the efficacy and safety of tislelizumab combined with Huaier granule as a first-line treatment for unresectable HCC, as well as its potential to improve patients' quality of life and alleviate HCC-related symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 years at the time of signing the informed consent form;
- •Histologically confirmed diagnosis of HCC;
- •BCLC stage C, or BCLC stage B disease that is unsuitable for locoregional therapy or has progressed after locoregional therapy, and is not eligible for curative treatment;
- •No prior systemic therapy for HCC. Note: Patients who have previously received local therapy (e.g., TACE) are not excluded;
- •Presence of ≥1 measurable lesion according to RECIST v1.1, provided that: the selected target lesion(s) have not been previously treated with local therapy, or the selected target lesion(s) are located within an area of prior local treatment and have subsequently been assessed as progressive disease according to RECIST v1.1;
- •Child-Pugh class A liver function within 7 days prior to randomization;
- •ECOG performance status ≤1.
排除标准
- •Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or mixed hepatocellular-cholangiocarcinoma;
- •Tumor thrombus involving the main portal vein or inferior vena cava;
- •Prior local liver therapy (e.g., transarterial chemoembolization, transarterial embolization, hepatic arterial infusion, radiotherapy, radioembolization, or ablation) or any immunotherapy (e.g., interleukin, interferon, thymosin, etc.) within 28 days before enrollment;
- •Use of traditional Chinese medicine or patent drugs for cancer control within 14 days before enrollment;
- •Grade 2 or higher hepatic encephalopathy at screening or in medical history;
- •Presence of pericardial effusion, uncontrolled pleural effusion, or clinically significant ascites at screening, defined as meeting either of the following criteria: (a) ascites detectable by physical examination at screening, or (b) ascites requiring paracentesis during screening;
- •History of severe hypersensitivity to other monoclonal antibodies;
- •Any clinical evidence of portal hypertension with bleeding esophageal or gastric varices during screening or within 6 months before randomization;
- •Toxicities from prior anticancer therapy have not resolved to baseline or stabilized, except for alopecia;
- •Any hemorrhagic or thrombotic disease within 6 months before screening, or any anticoagulant therapy requiring monitoring of the international normalized ratio (e.g., warfarin or similar agents);
- •History of any active malignancy within 2 years before screening, except for HCC under study in this trial and locally recurrent cancers that have been curatively treated (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast);
- •Known central nervous system metastases and/or leptomeningeal disease at screening;
- •Any active immunodeficiency or autoimmune disease at screening, and/or history of any immunodeficiency or autoimmune disease with potential for recurrence;
- •Any condition requiring systemic corticosteroid therapy (at doses >10 mg/day prednisone or equivalent of similar drugs) or other immunosuppressive treatment within 14 days before screening;
- •History of interstitial lung disease or non-infectious pneumonia, unless radiation-induced;
- •Any severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy at screening (e.g., tuberculosis), excluding viral hepatitis; known history of human immunodeficiency virus infection;
- •Presence of underlying medical conditions that, in the investigator's judgment, may pose risks for receiving the study treatment or complicate the interpretation of adverse events/toxicity;
- •History of allogeneic stem cell transplantation or organ transplantation; receipt of any live vaccine within 4 weeks before randomization (Note: seasonal influenza vaccines are generally inactivated and allowed; intranasal vaccines are live and not allowed);
- •Any major surgery within 28 days before randomization;
- •Female patients who are lactating.
研究组 & 干预措施
Tislelizumab plus Huaier granule
Experimental
干预措施: Tislelizumab plus Huaier granule (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: through study completion, an average of 1 year
次要结局
- Disease Control Rate(through study completion, an average of 1 year)
- Progression-Free Survival(From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
- Overall Survival(From date of treatment until the date of death from any cause, assessed up to 100 months)
- Incidence of Adverse Events(Within 30 days following the final administration.)
- Duration of Response(From date of documented objective tumor response until the date of the first recorded disease progression or death from any cause, whichever occurs first, assessed up to 100 months.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase II study: efficacy and safety of tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard chemotherapyHodgkin lymphoma2022-503090-11-00Fondazione Italiana Linfomi Onlus25
招募中
2 期
A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativaHidradenitis Suppurativa2024-519736-17-00Zura Bio Inc.90
尚未招募
2 期
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10NCT07304258Hebei Medical University30
招募中
3 期
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialNCT07388524National Cancer Institute (NCI)336
招募中
不适用
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast CancerNCT07358182Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300